GlobeNewswire by notified

LeddarTech Announces the Sensor Fusion and Perception Development Center Grand Opening in Tel Aviv, Israel, on June 9, 2022

Share

QUEBEC and TEL AVIV, Israel, May 24, 2022 (GLOBE NEWSWIRE) -- LeddarTech®, a global leader in providing the most flexible, robust and accurate ADAS and AD sensing technology, is pleased to announce the official grand opening of LeddarTech’s Sensor Fusion and Perception Development Center in Tel Aviv, Israel, June 9 at 3:00 p.m. (IST).

The event will be hosted by Charles Boulanger, CEO of LeddarTech and Ronny Cohen, Vice-President and General Manager of ADAS and AD Sensor Fusion and Perception. In addition to welcoming guests and dignitaries to the center, this event is also a celebration of our highly skilled and professional engineers and their contributions to our technology development.

The event will be operated in a casual mixer style with food, drinks and giveaways. There will also be a guest speaker presentation from Dr. Ami Appelbaum, Chairman of the Innovation Authority and Chief Scientist at the Ministry of Economy and Industry in Israel, who will discuss “Smart Mobility – Israel’s Potential, Opportunities and Risks.” In addition, guests will have the opportunity to meet the team, network and view demonstrations of the LeddarVision™ sensor fusion and perception platform. This platform enables Level 2-5 ADAS and AD on-road and off-road vehicles. LeddarVision combines AI and computer vision technologies and deep neural networks with computational efficiency to scale up the performance of ADAS/AD sensors and hardware essential for planning the driving path while providing safer autonomous driving with better detection.

“I am very proud to host this event in Israel,” stated Mr. Charles Boulanger, CEO of LeddarTech. “Our team in Israel, supported by our R&D facilities in Quebec and Ontario, has done an extraordinary job developing groundbreaking raw data fusion and perception technology.” Mr. Boulanger continued: “The Sensor Fusion and Perception Development Center in Tel Aviv marks a real achievement for LeddarTech as we continue to expand and engage with some of the best talent in the world,” Mr. Boulanger concluded.

About LeddarTech

Founded in 2007, LeddarTech is a comprehensive end-to-end environmental sensing company that enables customers to solve critical sensing, fusion and perception challenges across the entire value chain. LeddarTech provides cost-effective perception solutions scalable from Level 2 ADAS to Level 5 full autonomy with LeddarVision™, a raw-data sensor fusion and perception platform that generates a comprehensive 3D environmental model from a variety of sensor types and configurations. LeddarTech also supports LiDAR manufacturers and Tier 1-2 automotive suppliers with key technology building blocks such as LeddarSteer™ digital beam steering and the LeddarEngine™, which is built on LeddarTech’s Leddar™ technology employing patented signal acquisition and processing techniques to generate a richer and cleaner return signal at a lower cost. The LeddarEngine comprises a highly integrated, scalable LiDAR SoC and software combination that enables LiDAR developers and Tier 1-2 automotive suppliers to design their LiDAR solutions. The company is responsible for several innovations in cutting-edge automotive and mobility remote-sensing applications, with over 120 patented technologies (granted or pending) enhancing ADAS and autonomous driving capabilities.

Additional information about LeddarTech is accessible at www.leddartech.com and on LinkedIn, Twitter, Facebook and YouTube.

Contact:
Daniel Aitken, Vice-President, Global Marketing, Communications and Investor Relations, LeddarTech Inc.
Tel.: + 1-418-653-9000 ext. 232 daniel.aitken@leddartech.com

Investor relations contact:InvestorRelations@leddartech.com
https://investors.leddartech.com/

Leddar, LeddarTech, LeddarSteer, LeddarEngine, LeddarVision, LeddarSP, LeddarCore, LeddarEcho, VAYADrive, VayaVision, XLRator and related logos are trademarks or registered trademarks of LeddarTech Inc. and its subsidiaries. All other brands, product names and marks are or may be trademarks or registered trademarks used to identify products or services of their respective owners.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form